Clinical Trial Update: JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating baricitinib (JAK1/2 inhibitor) for adult idiopathic inflammatory myopathies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: University of Manchester | Conditions: Idiopathic Inflammatory Myopathies | Phase 2 | Status: COMPLETED